AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Comcast Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Dentsply Sirona Inc. (XRAY) â€� Form 4 insider transaction

Director Jonathan Jay Mazelsky reported the acquisition of 1,561.2862 phantom-stock units on 1 July 2025 under the company’s Directors� Deferred Compensation plan. Each unit is economically equivalent to one common share and will be settled in stock when the director leaves the board. The derivative units were credited at an indicative price of $16.01 per share, taking Mazelsky’s total deferred-compensation balance to 9,159.0102 units. No open-market cash purchase or sale of common shares was disclosed, and no changes were reported in non-derivative share ownership.

This filing signals continued alignment of the director’s long-term incentives with shareholder value but does not alter the public float or generate immediate dilution. As the grant stems from routine board compensation rather than an active investment decision, market impact is expected to be minimal.

Dentsply Sirona Inc. (XRAY) � Transazione insider Form 4

Il direttore Jonathan Jay Mazelsky ha comunicato l�acquisto di 1.561,2862 unità di azioni fantasma il 1° luglio 2025 nell’ambito del piano di compensazione differita per amministratori della società. Ogni unità corrisponde economicamente a un’azione ordinaria e sarà regolata in azioni al termine del mandato del direttore nel consiglio. Le unità derivati sono state accreditate a un prezzo indicativo di 16,01 $ per azione, portando il saldo totale della compensazione differita di Mazelsky a 9.159,0102 unità. Non sono state segnalate operazioni in denaro sul mercato aperto né variazioni nella proprietà di azioni non derivati.

Questa comunicazione indica un continuo allineamento degli incentivi a lungo termine del direttore con il valore per gli azionisti, ma non modifica il flottante pubblico né genera una diluizione immediata. Poiché l’assegnazione deriva da una normale compensazione del consiglio e non da una decisione di investimento attiva, l’impatto sul mercato è previsto minimo.

Dentsply Sirona Inc. (XRAY) � Transacción interna Formulario 4

El director Jonathan Jay Mazelsky informó la adquisición de 1,561.2862 unidades de acciones fantasma el 1 de julio de 2025 bajo el plan de compensación diferida para directores de la empresa. Cada unidad equivale económicamente a una acción común y se liquidará en acciones cuando el director deje la junta. Las unidades derivadas se acreditaron a un precio indicativo de $16.01 por acción, llevando el saldo total de compensación diferida de Mazelsky a 9,159.0102 unidades. No se revelaron compras o ventas en efectivo en el mercado abierto, ni cambios en la propiedad de acciones no derivadas.

Esta presentación indica una continua alineación de los incentivos a largo plazo del director con el valor para los accionistas, pero no altera el flotante público ni genera dilución inmediata. Dado que la concesión proviene de una compensación rutinaria del consejo en lugar de una decisión activa de inversión, se espera un impacto mínimo en el mercado.

Dentsply Sirona Inc. (XRAY) � Form 4 내부� 거래

ì´ì‚¬ Jonathan Jay MazelskyëŠ� 2025ë…� 7ì›� 1ì� 회사ì� ì´ì‚¬íš� ì´ì—° ë³´ìƒ ê³„íšì—� ë”°ë¼ 1,561.2862 팬텀 스톡 단위 ì·¨ë“ì� 보고했습니다. ê°� 단위ëŠ� 보통ì£� 1주와 경제ì ìœ¼ë¡� ë™ì¼í•˜ë©°, ì´ì‚¬ê°€ ì´ì‚¬íšŒì—ì„� 물러ë‚� ë•� 주ì‹ìœ¼ë¡œ ì •ì‚°ë©ë‹ˆë‹�. íŒŒìƒ ë‹¨ìœ„ëŠ� 주당 $16.01ì� 표시 가격으ë¡� ì ë¦½ë˜ì–´ Mazelskyì� ì´� ì´ì—° ë³´ìƒ ìž”ì•¡ì€ 9,159.0102 단위가 ë˜ì—ˆìŠµë‹ˆë‹�. 공개 시장ì—서 현금으로 보통주를 매매í•� ë‚´ì—­ì€ ì—†ìœ¼ë©�, 비파ìƒ� ì£¼ì‹ ì†Œìœ ê¶� ë³€ë™ë„ ë³´ê³ ë˜ì§€ 않았습니ë‹�.

ì� ì œì¶œì€ ì´ì‚¬ì� 장기 ì¸ì„¼í‹°ë¸Œê°€ 주주 가치와 ê³„ì† ì¼ì¹˜í•¨ì„ 나타내지ë§�, 공개 유통 ì£¼ì‹ ìˆ˜ì—ëŠ� 변화가 없으ë©� 즉ê°ì ì¸ í¬ì„ 효과ë� ë°œìƒí•˜ì§€ 않습니다. ì� ë³´ìƒì€ ì ê·¹ì ì¸ íˆ¬ìž ê²°ì •ì� 아닌 ì¼ìƒì ì¸ ì´ì‚¬íš� ë³´ìƒì—서 비롯ë� 것ì´ë¯€ë¡�, 시장 ì˜í–¥ì€ 최소ë¡� 예ìƒë©ë‹ˆë‹�.

Dentsply Sirona Inc. (XRAY) � Transaction d’initié Formulaire 4

Le directeur Jonathan Jay Mazelsky a déclaré l�acquisition de 1 561,2862 unités d’actions fantômes le 1er juillet 2025 dans le cadre du plan de rémunération différée des administrateurs de la société. Chaque unité équivaut économiquement à une action ordinaire et sera réglée en actions lorsque le directeur quittera le conseil d’administration. Les unités dérivées ont été créditées à un prix indicatif de 16,01 $ par action, portant le solde total de la rémunération différée de Mazelsky à 9 159,0102 unités. Aucune opération d’achat ou de vente d’actions ordinaires en espèces sur le marché ouvert n’a été divulguée, et aucun changement dans la détention d’actions non dérivées n’a été signalé.

Ce dépôt signale un alignement continu des incitations à long terme du directeur avec la valeur actionnariale, mais n’altère pas le flottant public ni ne génère de dilution immédiate. Comme cette attribution découle d’une rémunération habituelle du conseil plutôt que d’une décision d’investissement active, l’impact sur le marché est attendu comme minimal.

Dentsply Sirona Inc. (XRAY) � Form 4 Insider-Transaktion

Der Direktor Jonathan Jay Mazelsky meldete am 1. Juli 2025 den Erwerb von 1.561,2862 Phantomaktieneinheiten im Rahmen des Directors� Deferred Compensation Plans des Unternehmens. Jede Einheit entspricht wirtschaftlich einer Stammaktie und wird bei Ausscheiden des Direktors aus dem Vorstand in Aktien ausgezahlt. Die Derivateinheiten wurden zu einem indikativem Preis von 16,01 $ pro Aktie gutgeschrieben, wodurch Mazelskys Gesamtguthaben an aufgeschobener Vergütung auf 9.159,0102 Einheiten anstieg. Es wurden keine Bartransaktionen auf dem offenen Markt gemeldet, ebenso wenig Änderungen im Besitz von nicht-derivativen Aktien.

Diese Meldung signalisiert eine fortgesetzte Ausrichtung der langfristigen Anreize des Direktors am Aktionärswert, verändert jedoch nicht den Streubesitz und verursacht keine sofortige Verwässerung. Da die Zuteilung aus der routinemäßigen Vorstandsvergütung und nicht aus einer aktiven Investitionsentscheidung resultiert, wird ein minimaler Markteinfluss erwartet.

Positive
  • Director increases deferred equity stake, enhancing alignment with shareholder interests without immediate dilution.
  • No shares sold; transaction reflects commitment rather than profit-taking.
Negative
  • None.

Insights

TL;DR: Routine deferred-comp grant; minor positive alignment, negligible market impact.

The Form 4 shows a standard quarterly credit to the director’s phantom-stock account. Because phantom stock is settled only upon board departure, no shares enter circulation today, eliminating dilution risk. The pricing at $16.01 merely reflects XRAY’s reference price at grant and carries no strike or conversion premium. Total holdings of roughly 9.2 k units represent <0.01 % of shares outstanding, an immaterial stake for valuation but a reasonable incentive for governance alignment. Overall, the transaction is neutral-to-slightly positive for investors as it reinforces long-term stewardship without cash outflow or signaling concerns.

Dentsply Sirona Inc. (XRAY) � Transazione insider Form 4

Il direttore Jonathan Jay Mazelsky ha comunicato l�acquisto di 1.561,2862 unità di azioni fantasma il 1° luglio 2025 nell’ambito del piano di compensazione differita per amministratori della società. Ogni unità corrisponde economicamente a un’azione ordinaria e sarà regolata in azioni al termine del mandato del direttore nel consiglio. Le unità derivati sono state accreditate a un prezzo indicativo di 16,01 $ per azione, portando il saldo totale della compensazione differita di Mazelsky a 9.159,0102 unità. Non sono state segnalate operazioni in denaro sul mercato aperto né variazioni nella proprietà di azioni non derivati.

Questa comunicazione indica un continuo allineamento degli incentivi a lungo termine del direttore con il valore per gli azionisti, ma non modifica il flottante pubblico né genera una diluizione immediata. Poiché l’assegnazione deriva da una normale compensazione del consiglio e non da una decisione di investimento attiva, l’impatto sul mercato è previsto minimo.

Dentsply Sirona Inc. (XRAY) � Transacción interna Formulario 4

El director Jonathan Jay Mazelsky informó la adquisición de 1,561.2862 unidades de acciones fantasma el 1 de julio de 2025 bajo el plan de compensación diferida para directores de la empresa. Cada unidad equivale económicamente a una acción común y se liquidará en acciones cuando el director deje la junta. Las unidades derivadas se acreditaron a un precio indicativo de $16.01 por acción, llevando el saldo total de compensación diferida de Mazelsky a 9,159.0102 unidades. No se revelaron compras o ventas en efectivo en el mercado abierto, ni cambios en la propiedad de acciones no derivadas.

Esta presentación indica una continua alineación de los incentivos a largo plazo del director con el valor para los accionistas, pero no altera el flotante público ni genera dilución inmediata. Dado que la concesión proviene de una compensación rutinaria del consejo en lugar de una decisión activa de inversión, se espera un impacto mínimo en el mercado.

Dentsply Sirona Inc. (XRAY) � Form 4 내부� 거래

ì´ì‚¬ Jonathan Jay MazelskyëŠ� 2025ë…� 7ì›� 1ì� 회사ì� ì´ì‚¬íš� ì´ì—° ë³´ìƒ ê³„íšì—� ë”°ë¼ 1,561.2862 팬텀 스톡 단위 ì·¨ë“ì� 보고했습니다. ê°� 단위ëŠ� 보통ì£� 1주와 경제ì ìœ¼ë¡� ë™ì¼í•˜ë©°, ì´ì‚¬ê°€ ì´ì‚¬íšŒì—ì„� 물러ë‚� ë•� 주ì‹ìœ¼ë¡œ ì •ì‚°ë©ë‹ˆë‹�. íŒŒìƒ ë‹¨ìœ„ëŠ� 주당 $16.01ì� 표시 가격으ë¡� ì ë¦½ë˜ì–´ Mazelskyì� ì´� ì´ì—° ë³´ìƒ ìž”ì•¡ì€ 9,159.0102 단위가 ë˜ì—ˆìŠµë‹ˆë‹�. 공개 시장ì—서 현금으로 보통주를 매매í•� ë‚´ì—­ì€ ì—†ìœ¼ë©�, 비파ìƒ� ì£¼ì‹ ì†Œìœ ê¶� ë³€ë™ë„ ë³´ê³ ë˜ì§€ 않았습니ë‹�.

ì� ì œì¶œì€ ì´ì‚¬ì� 장기 ì¸ì„¼í‹°ë¸Œê°€ 주주 가치와 ê³„ì† ì¼ì¹˜í•¨ì„ 나타내지ë§�, 공개 유통 ì£¼ì‹ ìˆ˜ì—ëŠ� 변화가 없으ë©� 즉ê°ì ì¸ í¬ì„ 효과ë� ë°œìƒí•˜ì§€ 않습니다. ì� ë³´ìƒì€ ì ê·¹ì ì¸ íˆ¬ìž ê²°ì •ì� 아닌 ì¼ìƒì ì¸ ì´ì‚¬íš� ë³´ìƒì—서 비롯ë� 것ì´ë¯€ë¡�, 시장 ì˜í–¥ì€ 최소ë¡� 예ìƒë©ë‹ˆë‹�.

Dentsply Sirona Inc. (XRAY) � Transaction d’initié Formulaire 4

Le directeur Jonathan Jay Mazelsky a déclaré l�acquisition de 1 561,2862 unités d’actions fantômes le 1er juillet 2025 dans le cadre du plan de rémunération différée des administrateurs de la société. Chaque unité équivaut économiquement à une action ordinaire et sera réglée en actions lorsque le directeur quittera le conseil d’administration. Les unités dérivées ont été créditées à un prix indicatif de 16,01 $ par action, portant le solde total de la rémunération différée de Mazelsky à 9 159,0102 unités. Aucune opération d’achat ou de vente d’actions ordinaires en espèces sur le marché ouvert n’a été divulguée, et aucun changement dans la détention d’actions non dérivées n’a été signalé.

Ce dépôt signale un alignement continu des incitations à long terme du directeur avec la valeur actionnariale, mais n’altère pas le flottant public ni ne génère de dilution immédiate. Comme cette attribution découle d’une rémunération habituelle du conseil plutôt que d’une décision d’investissement active, l’impact sur le marché est attendu comme minimal.

Dentsply Sirona Inc. (XRAY) � Form 4 Insider-Transaktion

Der Direktor Jonathan Jay Mazelsky meldete am 1. Juli 2025 den Erwerb von 1.561,2862 Phantomaktieneinheiten im Rahmen des Directors� Deferred Compensation Plans des Unternehmens. Jede Einheit entspricht wirtschaftlich einer Stammaktie und wird bei Ausscheiden des Direktors aus dem Vorstand in Aktien ausgezahlt. Die Derivateinheiten wurden zu einem indikativem Preis von 16,01 $ pro Aktie gutgeschrieben, wodurch Mazelskys Gesamtguthaben an aufgeschobener Vergütung auf 9.159,0102 Einheiten anstieg. Es wurden keine Bartransaktionen auf dem offenen Markt gemeldet, ebenso wenig Änderungen im Besitz von nicht-derivativen Aktien.

Diese Meldung signalisiert eine fortgesetzte Ausrichtung der langfristigen Anreize des Direktors am Aktionärswert, verändert jedoch nicht den Streubesitz und verursacht keine sofortige Verwässerung. Da die Zuteilung aus der routinemäßigen Vorstandsvergütung und nicht aus einer aktiven Investitionsentscheidung resultiert, wird ein minimaler Markteinfluss erwartet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NOVAK DAVID C

(Last) (First) (Middle)
ONE COMCAST CENTER

(Street)
PHILADELPHIA PA 19103

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
COMCAST CORP [ CMCSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/30/2025 A 946 A $0.0000 379,284.299 D
Class A Common Stock 500 I By Trusts
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Elizabeth Wideman, Attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did XRAY director Jonathan Mazelsky report in the latest Form 4?

He acquired 1,561.2862 phantom-stock units on 07/01/2025 under the deferred-compensation plan.

Does the phantom-stock grant create dilution for Dentsply Sirona shareholders?

No. Phantom stock is settled in shares only after the director leaves the board, so no new shares are issued today.

At what price were the phantom-stock units credited?

The reference price recorded was $16.01 per underlying common share.

How many phantom-stock units does Mazelsky now hold in total?

After the grant, his total stands at 9,159.0102 units.

Were any open-market purchases or sales of XRAY common stock reported?

No. The filing shows only a deferred-compensation acquisition; no common shares were bought or sold.
Comcast Corp

NASDAQ:CMCSA

CMCSA Rankings

CMCSA Latest News

CMCSA Latest SEC Filings

CMCSA Stock Data

131.46B
3.70B
0.72%
89.08%
1.38%
Telecom Services
Cable & Other Pay Television Services
United States
PHILADELPHIA